Kannalife, Inc. Stock Price - KLFE

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Kannalife, Inc. KLFE OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 1.20 0.00 0.00 0.00 1.20 19:00:00
Bid Price Ask Price Spread Spread % News
1.20 1.50 0.30 20.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Kannalife, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 89.07M 74.23M $ 936.82k - - 7.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Kannalife, Inc. News

Loading Messages....

Latest KLFE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KLFE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.651.701.201.204,500-0.45-27.27%
1 Month1.651.701.201.204,500-0.45-27.27%
3 Months1.651.701.201.204,500-0.45-27.27%
6 Months1.651.701.201.204,500-0.45-27.27%
1 Year1.651.701.201.204,500-0.45-27.27%
3 Years1.651.701.201.204,500-0.45-27.27%
5 Years1.651.701.201.204,500-0.45-27.27%

Kannalife, Inc. Description

Kannalife, Inc. ("Kannalife"), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife currently holds an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a "super-CBD" and was recently awarded U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy". Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.


Your Recent History
USOTC
KLFE
Kannalife,..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.